The long-term goal of our studies is to develop new diagnostic methods and therapeutic regiments for urologic cancers. We are in the process of identifying molecular and genetic changes of these cancers that correlate with the cancer disease behaviors, both clinically and pathologically.
Our laboratory, supported by Urology, Pathology and the MGH Cancer Center, enjoys extensive collaborations with other members of the researcher community both locally or around the World. We often provide clinical, research and technical expertise as well as pathology specimens to these collaborative studies.
Shulin Wu, MD, PhD
Sharron X. Lin, PhD
Min Zhang, MD, PhD
Haitao Liu, MD
Sandra D. Kirley, BS
Prostate cancer is the most common cancer and the second leading cause of cancer death of men in the US. We are interested in identifying the genes or gene expression profiles associated with the development, diagnosis and prognosis of prostate cancer.
Bladder cancer is responsible for more than 130,000 deaths annually worldwide and is the fifth most common solid malignancy in the United States. We are studying genes that are associated with bladder cancer progression.
Kidney cancer is difficult to screen and detect in its early stage when surgical treatment is most effective. We are interested in molecular markers that are associated with aggressive outcome of the cancer.
MGH Hotline 06.18.10 On the eve of the MGH bicentennial, one MGH department proudly celebrates its centennial.
Publications in 20091. Feldman AS, Banyard J, Wu C-L, McDougal W.S. and BR Zetter. Cystatin B as a tissue and urinary biomarker of bladder cancer recurrence and disease progression. Clinical Cancer Research, 2009;15(3):1024-31.
Publications in 20101. C.-L. Wu, K. W. Jordan, E. M. Ratai, J. Sheng, C. B. Adkins, E. M. DeFeo, B. G. Jenkins, L. Ying, W. S. McDougal, L. L. Cheng, Metabolomic imaging for human prostate cancer detection. Sci. Transl. Med. 2, 16ra8 (2010).
Hours: 8:00 am to 4:00 pm M, T, W, F; 9:30 am to 4:00 pm, Th
Public Transportation Access: yes
Disabled Access: yes
For appointments for patients who do not have a urologist:
For administrative or residency program questions: